Takeda Ventures was among the participants in a $46.5m round closed nearly a year after its parent company launched a partnership with the Institut Curie spinout.

Egle Therapeutics, a France-based T-cell therapy developer spun out of Institut Curie, closed a €40m ($46.5m) series A round late last month that included Takeda Ventures, the strategic investment arm of pharmaceutical firm Takeda.

Public investment bank Bpifrance’s InnoBio 2 fund co-led the round with life sciences investment firm LSP, and it also featured venture capital fund Fund+ and investment firm Bioqube Ventures.

Egle is working on immunotherapies designed to fight cancer and autoimmune diseases by targeting immune suppressor regulatory…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?